DARIUS N. LAKDAWALLA

Schaeffer Center for Health Policy and Economics (213) 538-8736

University of Southern California dlakdawa@usc.edu

635 Downey Way, VPD #414-K

Los Angeles, CA 90089-3331

#### Education

*University of Chicago.* Ph.D. in Economics, June 2000.

*Amherst College*. B.A., Mathematics and Philosophy, 1995. Summa Cum Laude, Phi Beta Kappa.

#### Professional Experience

2018-present *Director of Research,* Leonard D. Schaeffer Center for Health Economics and Policy, University of Southern California

2012-present: *Quintiles Chair in Pharmaceutical Development and Regulatory Innovation*,
University of Southern California

2012-present: *Full Professor*, School of Pharmacy, University of Southern California

2012-present: *Full Professor*, Price School of Public Policy, University of Southern California

2009-present: *Affiliated Adjunct Economist*, RAND Corporation

2009-2013: *Director of Research*, Leonard D. Schaeffer Center for Health Economics and Policy,
University of Southern California

2009-2012: *Associate Professor (with tenure)*, School of Policy, Planning, and Development,
University of Southern California

2007-2009: *Director of Research*, Bing Center for Health Economics, RAND Corporation.

2006-2009: *Senior Economist*, RAND Corporation

2003-2006: *Economist*, RAND Corporation

2000-2003: *Associate Economist*, RAND Corporation

#### Other Positions

2019-present: *Expert Panel Member,* “Addressing Sickle Cell Disease,” National Academy of Medicine

2019-present: *Co-Chair,* Aspen Institute/USC Blue-Ribbon Panel on Health Technology Assessment in the U.S.

2018-2019: *Program Chair, Pharmaceutical Economics and Policy*, American Society of Health Economists 2019 Annual Meeting

2016-present: *Associate Editor*, *Journal of Health Economics*

2014-present: *Associate Editor,* *American Journal of Health Economics*

2013-present: *Editorial Board Member*, *American Journal of Managed Care: Evidence-Based Diabetes*

2012-present: *Editorial Board Member*, *American Journal of Managed Care: Evidence-Based Oncology*

2012-2019: *Associate Editor*, *Review of Economics and Statistics*

2010-2014: *Visiting Scholar*, American Enterprise Institute

2009-present: *Research Associate*, National Bureau of Economic Research, Cambridge, MA Program Memberships in Health Care and Health Economics

2005-present: *Editorial Board Member*, *BE Press Forum on Health Economics and Policy*

2001-2009: *Faculty Research Fellow*, National Bureau of Economic Research, Cambridge, MA. Program Memberships in Health Care and Health Economics

2002-2009: *Professor of Economics*, Pardee RAND Graduate School of Public Policy, Santa Monica, CA

#### Peer-Reviewed Publications

#### *Economics Literature*

1. Helland, Eric, **Darius N. Lakdawalla**, Anup Malani, and Seth Seabury. “Unintended consequences of products liability: Evidence from the pharmaceutical market.” *Journal of Law, Economics, and Organization* (forthcoming).
2. Myerson, Rebecca, Reginald Tucker-Seeley, Dana Goldman, and **Darius N. Lakdawalla**. “Does Medicare improve cancer detection and mortality outcomes?” *Journal of Policy Analysis and Management* (forthcoming).
3. **Lakdawalla, Darius** and Charles Phelps. “Health Technology Assessment with Risk Aversion in Health.” *Journal of Health Economics,* 72, July 2020. DOI: https://doi.org/10.1016.j.jhealeco.2020.102346.
4. Chen, Alice and **Darius N. Lakdawalla**. “Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses.” *Journal of Health Economics* (2019), DOI: 10.1016/j.healeco.2019.02.001.
5. **Lakdawalla, Darius**. “The Economics of the Pharmaceutical Industry.” *Journal of Economic Literature*, vol. 56, no. 2, June 2018, pp. 397-449.
6. **Lakdawalla, Darius N.,** Anup Malani and Julian Reif. "The Insurance Value of Medical Innovation." *Journal of Public Economics*, vol. 145, 2017, pp. 94-102.
7. **Lakdawalla, Darius N.,** Joanna MacEwan, Robert Dubois, Kimberly Westrich, Mikel Berdud and Adrian Towse. "What Do Pharmaceuticals Really Cost in the Long Run?" *American Journal of Managed Care*, vol. 23, no. 8, 2017, pp. 488-493.
8. Bognar, Katalin, John Romley, Jay Bae, James Murray, Jacquelyn Chou and **Darius N. Lakdawalla**. "The Role of Imperfect Surrogate Endpoint Information in Drug Approval and Reimbursement Decisions." *Journal of Health Economics*, vol. 51, 2017, pp. 1-12.
9. **Lakdawalla, Darius** and Wesley Yin. "Insurers' Negotiating Leverage and the External Effects of Medicare Part D." *Review of Economics and Statistics*, vol. 97, no. 2, 2015, pp. 314-331.
10. Kaestner, Robert, Michael Darden and **Darius N. Lakdawalla**. "Are Investments in Disease Prevention Complements? The Case of Statins and Health Behaviors." *Journal of Health Economics*, vol. 36, 2014, pp. 151-163.
11. **Lakdawalla, Darius N.,** Neeraj Sood and Qian Gu. "Pharmaceutical Advertising and Medicare Part D." *Journal of Health Economics*, vol. 32, no. 6, 2013, pp. 1356-1367.
12. **Lakdawalla, Darius** and Neeraj Sood. "Health Insurance as a Two-Part Pricing Contract." *Journal of Public Economics*, vol. 102, 2013, pp. 1-12.
13. Michaud, Pierre-Carl, Dana Goldman, **Darius N. Lakdawalla**, Yuhui Zheng and Adam Gailey. "The Value of Medical and Pharmaceutical Interventions for Reducing Obesity." *Journal of Health Economics*, vol. 31, no. 4, 2012, pp. 630-643.
14. **Lakdawalla, Darius** and Seth Seabury. "The Welfare Effects of Medical Malpractice Liability." *International Review of Law and Economics*, vol. 32, no. 4, 2012, pp. 356-369.
15. **Lakdawalla, Darius** and George Zanjani. "Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk Transfer." *Journal of Risk and Insurance*, vol. 79, no. 2, 2012, pp. 449-476.
16. **Lakdawalla, Darius** and Tomas Philipson. "Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets." *Journal of Law and Economics*, vol. 55, no. 1, 2012, pp. 151-187.
17. Philipson, Tomas, Seth Seabury, Lee Lockwood, Dana Goldman and **Darius N. Lakdawalla**. "Geographic Variation in Health Care: The Role of Private Markets." *Brookings Papers on Economic Activity*, 2010, pp. 325-361.
18. **Lakdawalla, Darius N.,** Eric Sun, Anupam Jena, Carolina Reyes, Tomas Philipson and Dana Goldman. "An Economic Evaluation of the War on Cancer." *Journal of Health Economics*, 2010, vol. 29, no. 3, pp. 333-346.
19. **Lakdawalla, Darius** and Neeraj Sood. "Innovation and the Welfare Effects of Public Drug Insurance." *Journal of Public Economics*, vol. 93, no. 3-4, 2009, pp. 541-548.
20. **Lakdawalla, Darius** and Tomas Philipson. "The Growth of Obesity and Technological Change." *Economics and Human Biology*, vol. 7, no. 3, 2009, pp. 283-293.
21. **Lakdawalla, Darius** and Tomas Philipson. "Labor Supply and Weight." *Journal of Human Resources*, vol. 42, no. 1, 2007, pp. 85-116.
22. Berrebi, Claude and **Darius N. Lakdawalla**. "How Does Terrorism Risk Vary across Space and Time? An Analysis Based on the Israeli Experience." *Defence and Peace Economics*, vol. 18, no. 2, 2007, pp. 113-131.
23. **Lakdawalla, Darius N.,** Robert Reville and Seth Seabury. "How Does Health Insurance Affect Workers' Compensation Filing." *Economic Inquiry*, 2007, vol. 45, no. 2, pp. 286-303.
24. **Lakdawalla, Darius** and Tomas Philipson. "Nonprofit Production and Industry Performance." *Journal of Public Economics*, vol. 90, 2006, pp. 1681-1698
25. **Lakdawalla, Darius N.,** Neeraj Sood and Dana Goldman. "HIV Breakthroughs and Risky Sexual Behavior." *Quarterly Journal of Economics*, vol. 121, no. 3, 2006, pp. 1063-1102.
26. **Lakdawalla, Darius**. "The Economics of Teacher Quality." *Journal of Law and Economics*, vol. 49, 2006, pp. 285-329.
27. Bhattacharya, Jay and **Darius N. Lakdawalla**. "Does Medicare Benefit the Poor?" *Journal of Public Economics*, vol. 90, no. 1-2, 2006, pp. 277-292.
28. **Lakdawalla, Darius** and George Zanjani. "Insurance, Self-Protection, and the Economics of Terrorism." *Journal of Public Economics*, vol. 89, no. 9, 2005, pp. 1891-1905.
29. Goldman, Dana and **Darius N. Lakdawalla**. "A Theory of Health Disparities and Medical Technology." *B.E. Journals in Economic Analysis and Policy: Contributions to Economic Analysis and Policy*, vol. 4, no. 1, 2005, pp. 1-30.
30. Bhattacharya, Jay and **Darius N. Lakdawalla**. "The Labor Market Value of Health Improvements." *BE Press Forum for Health Economics and Policy, Forum: Biomedical Research and the Economy*, vol. Article 2, 2005.
31. **Lakdawalla, Darius** and Neeraj Sood. "Social Insurance and the Design of Innovation Incentives." *Economics Letters*, vol. 85, no. 1, 2004, pp. 57-61.
32. **Lakdawalla, Darius** and Tomas Philipson. "The Rise in Old-Age Longevity and the Market for Long-Term Care." *American Economic Review*, vol. 92, no. 1, 2002, pp. 295-306.

#### *Health Services and Health Policy Literature*

1. Baumgardner, James R., Michelle S. Brauer, Jie Zhang, Yanni Hao, Zhimei Liu, and **Darius N. Lakdawalla**. “CAR-T therapy and historical trends in effectiveness and cost-effectiveness of oncology treatments.” *Journal of Comparative Effectiveness Research*, February 14, 2020. DOI: https://doi.org/10.2217/cer-2019-0065.
2. Shih, Tiffany M, Kavita Sail, Yash Jalundhwala, Jeffrey Sullivan, Emma van Eijndhoven, Cindy Zadikoff, Thomas Marshall, and **Darius N. Lakdawalla**. “The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson’s disease.” *Journal of Medical Economics,* DOI: [10.1080/13696998.2019.1693383](https://doi.org/10.1080/13696998.2019.1693383).
3. MacEwan, Joanna P., Jason Doctor, Karen Mulligan, Suepattra G. May, Katherine Batt, Christopher Zacker, **Darius N. Lakdawalla**, Dana Goldman. “The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers.” *MDM Policy & Practice*, 4(1), June 2019, DOI: <https://doi.org/10/1177/2381468319855386>.
4. Sussell, Jesse, Jacqueline Vanderpuye-Orgle, Diana Vania, Hans-Peter Goertz, and **Darius N. Lakdawalla**. “Understanding price growth in the market for targeted oncology therapies.” *American Journal of Managed Care*, 25(6): 273-277, June 2019.
5. Incerti, Devin, Jeffrey Curtis, Jason Shafrin, **Darius N. Lakdawalla**, and Jeroen P. Jansen. “A flexible open-source decision model for value assessment of biologic treatment for rheumatoid arthritis.” *Pharmacoeconomics* 37(6): 829-843, June 2019.
6. Jena, Anupam Bapu, Julia Thornton Snider, Oliver Diaz Espinosa, Andy Ingram, Yuri Sanchez Gonzalez, and **Darius N. Lakdawalla**. “How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom?” *Value in Health*, Vol. 22, Issue 6, 2019, pp. 669-676.
7. Baumgardner, James, Ahva Shahabi, Christopher Zacker, and **Darius N. Lakdawalla**. “Cost Variation and Savings Opportunities in the Oncology Care Model.” *The American Journal of Managed Care*, 24(12), December 2018, pp. 618-623.
8. Jena, Anupam B., Jacquelyn W. Chou, Lara Yoon, Wade M. Aubry, Jan Berger, Wayne Burton, A. Mark Fendrick, Donna M. Fick, David Franklin, Rebecca Killion, **Darius N. Lakdawalla**, Peter J. Neumann, Kavita Patel, John Yee, Brian Sakurada, Kristina Yu-Isenberg. “Understanding and Improving Value Frameworks with Real-world Patient Outcomes.” *The American Journal of Managed Care*, 24(11), November 2018, pp. 506-509.
9. Sachs, Rachel, Nicholas Bagley and **Darius N. Lakdawalla**. "Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule." *Journal of Health Politics, Policy and Law.*, vol. 43, no. 1, 2018, pp. 5-18.
10. Phelps, Charles, **Darius N. Lakdawalla**, Anirban Basu, Michael Drummond, Adrian Towse, and Patricia Danzon. "Approaches to Aggregation and Decision Making-a Health Economics Approach: An ISPOR Special Task Force Report [5]." *Value in Health*, vol. 21, no. 2, 2018, pp. 146-154.
11. **Lakdawalla, Darius N.,** Jalpa Doshi, Louis Garrison, Charles Phelps, Anirban Basu, and Patricia Danzon. "Defining Elements of Value in Health Care-a Health Economics Approach: An ISPOR Special Task Force Report [3]." *Value in Health*, vol. 21, no. 2, 2018, pp. 131-139.
12. Garrison, Louis, Peter Neumann, Richard Willke, Anirban Basu, Patricia Danzon, Jalpa Doshi, Michael Drummond, **Darius N. Lakdawalla**, Mark Pauly, Charles Phelps, Scott Ramsey, Adrian Towse and Milton Weinstein. "A Health Economics Approach to Us Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]." *Value in Health*, vol. 21, no. 2, 2018, pp. 161-165.
13. Shafrin, Jason, Felicia Forma, Ethan Scherer, Ainslie Hatch, Edward Vytlacil and **Darius N. Lakdawalla**. "The Cost of Adherence Mismeasurement in Serious Mental Illness: A Claims-Based Analysis." *American Journal of Managed Care*, vol. 23, no. 5, 2017, pp. e156-e163.
14. **Lakdawalla, Darius N.,** Jason Shafrin, Ningqi Hou, Desi Peneva, Seanna Vine, Jinhee Park, Jie Zhang, Ron Brookmeyer and Robert Figlin. "Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework." *Value in Health*, vol. 20, no. 7, 2017, pp. 866-875.
15. Stevens, Warren, Desi Peneva, Jim Li, Larry Liu, Gordon Liu, Runlin Gao and **Darius N. Lakdawalla**. "Estimating the Future Burden of Cardiovascular Disease and the Value of Lipid and Blood Pressure Control Therapies in China." *BMC Health Services Research*, vol. 16, no. 175, 2016.
16. Shih, Tiffany, Craig Wakeford, Dennis Meletiche, Jesse Sussell, Adrienne Chung, Yanmei Liu, Jin Joo Shim and **Darius N. Lakdawalla**. "Reconsidering the Economic Value of Multiple Sclerosis Therapies." *American Journal of Managed Care*, vol. 22, no. 11, 2016, pp. e368-e374.
17. Shafrin, Jason, Taylor Schwartz, **Darius N. Lakdawalla** and Felicia Forma. "Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia." *Journal of Managed Care and Specialty Pharmacy*, vol. 22, no. 11, 2016, pp. 1285-1291.
18. Shafrin, Jason, Ron Brookmeyer, Desi Peneva, Jinhee Park, Jie Zhang, Robert Figlin and **Darius N. Lakdawalla**. "The Value of Surrogate Endpoints for Predicting Real-World Survival across Five Cancer Types." *Current Medical Research and Opinion*, vol. 32, no. 4, 2016, pp. 731-739.
19. Moreno, Gigi, Karen Mulligan, Caroline Huber, Mark Linthicum, David Dreyfus, Timothy Juday, Steven Marx, Yuri Gonzalez, Ron Brookmeyer and **Darius N. Lakdawalla**. "Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment." *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP236-244.
20. MacEwan, Joanna, Felicia Forma, Jason Shafrin, Ainslie Hatch, **Darius N. Lakdawalla** and J. P. Lindenmayer. "Patterns of Adherence to Oral Atypical Antipsychotics among Patients Diagnosed with Schizophrenia." *Journal of Managed Care and Specialty Pharmacy*, vol. 22, no. 11, 2016, pp. 1349-1361.
21. Linthicum, Mark, Yuri Gonzalez, Karen Mulligan, Gigi Moreno, David Dreyfus, Timothy Juday, Steven Marx, **Darius N. Lakdawalla**, Brian Edlin and Ron Brookmeyer. "Value of Expanding HCV Screening and Treatment Policies in the United States." *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP227-235.
22. Jena, Anupam, Warren Stevens, Yuri Gonzalez, Steven Marx, Timothy Juday, **Darius N. Lakdawalla** and Tomas Philipson. "The Wider Public Health Value of HCV Treatment Accrued by Liver Transplant Recipients." *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP212-219.
23. Seabury, Seth, **Darius N. Lakdawalla**, J. Samantha Dougherty, Jesse Sullivan and Dana Goldman. "Medication Adherence and Measures of Health Plan Quality." *American Journal of Managed Care*, vol. 21, no. 6, 2015, pp. e379-389.
24. Romley, John, Sarah Axeen, **Darius N. Lakdawalla**, Matthew Chernew, Jay Bhattacharya and Dana Goldman. "The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization." *Health Services Research.*, vol. 50, no. 3, 2015, pp. 883-896.
25. Linthicum, Mark, Julia Thornton Snider, Rhema Vaithianathan, Yanyu Wu, Chris LaVallee, **Darius N. Lakdawalla**, Jennifer Benner and Tomas Philipson. "Economic Burden of Disease-Associated Malnutrition in China." *Asia Pacific Journal of Public Health*, vol. 27, no. 4, 2015, pp. 407-417.
26. **Lakdawalla, Darius N.,** Jason Shafrin, Claudio Lucarelli, Sean Nicholson, Zeba Khan and Tomas Philipson. "Quality-Adjusted Cost of Care: A Meaningful Way to Measure Growth in Innovation Cost Versus the Value of Health Gains." *Health Affairs*, vol. 34, no. 4, 2015, pp. 555-561.
27. Eber, Michael., Dana Goldman, **Darius N. Lakdawalla**, Tomas Philipson, Daryl Pritchard, M. Marco Huesch, Nicholas Summers, Mark Linthicum, Jesse Sullivan and Robert Dubois. "Clinical Evidence Inputs to Comparative Effectiveness Research Could Impact the Development of Novel Treatments." *Journal of Comparative Effectiveness Research*, 2015, pp. 1-11.
28. Seabury, Seth, Dana Goldman, Iftekhar Kalsekar, John Sheehan, Kimberly Laubmeier and **Darius N. Lakdawalla**. "Formulary Restrictions on Atypical Antipsychotics: Impact on Costs for Patients with Schizophrenia and Bipolar Disorder in Medicaid." *American Journal of Managed Care*, vol. 20, no. 2, 2014, pp. e52-60.
29. Mangalmurti, S., Seth Seabury, Amitabh Chandra, **Darius N. Lakdawalla**, William Oetgen and Anupam Jena. "Medical Professional Liability Risk among U.S. Cardiologists." *American Heart Journal*, vol. 167, no. 5, 2014, pp. 690-696.
30. **Lakdawalla, Darius N.,** Julia Snider, Daniella Perlroth, Chris LaVallee, Mark Linthicum, Tomas Philipson, Jamie Partridge and Paul Wischmeyer. “Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?” *Forum for Health Economics and Policy*, vol. 17, no. 2, 2014, pp. 131-151.
31. Gupta, Charu, Glenn Chertow, Mark Linthicum, Karen Van Nuys, Vasily Belozeroff, Darryl Quarles and **Darius N. Lakdawalla**. "Reforming Medicare's Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism." *Health Services Research.*, vol. 49, no. 6, 2014, pp. 1925-1943.
32. Goldman, Dana, Joel Fastenau, Riad Dirani, Eric Helland, Geoffrey Joyce, Ryan Conrad and **Darius N. Lakdawalla**. "Medicaid Prior Authorization Policies and Imprisonment among Patients with Schizophrenia." *American Journal of Managed Care*, vol. 20, no. 7, 2014, pp. 577-586.
33. Seabury, Seth, Amitabh Chandra, **Darius N. Lakdawalla** and Anupam Jena. "On Average, Physicians Spend Nearly 11 Percent of Their 40-Year Careers with an Open, Unresolved Malpractice Claim." *Health Affairs,* vol. 32, no. 1, 2013, pp. 111-119.
34. Philipson, Tomas, Julia Snider, **Darius N. Lakdawalla**, Benoit Stryckman and Dana Goldman. "Impact of Oral Nutritional Supplementation on Hospital Outcomes." *American Journal of Managed Care*, vol. 19, no. 2, 2013, pp. 121-128.
35. **Lakdawalla, Darius N.,** Mintu Turakhia, Mehul Jhaveri, Essy Mozaffari, Pamela Davis, Lily Bradley and Matthew Solomon. "Comparative Effectiveness of Antiarrhythmic Drugs on Cardiovascular Hospitalization and Mortality in Atrial Fibrillation." *Journal of Comparative Effectiveness Research*, vol. 2, no. 3, 2013, pp. 301-312.
36. **Lakdawalla, Darius N.,** Michael Eber, Felicia Forma, Jesse Sullivan, Pierre-Carl Michaud, Lily Bradley and Dana Goldman. "Measuring the Value of Better Diabetes Management." *American Journal of Managed Care*, vol. 19 Spec No. 2, 2013, p. E11.
37. Goldman, Dana, Charu Gupta, Eshan Vasudeva, Kostas Trakas, Ralph Riley, **Darius N. Lakdawalla**, David Agus, Neeraj Sood, Anupam Jena and Tomas Philipson. "The Value of Diagnostic Testing in Personalized Medicine." *Forum for Health Economics and Policy*, vol. 16, no. 2, 2013, pp. 121-133.
38. Chernew, Michael, Rick McKellar, Wade Aubry, Roy Beck, Jennifer Benner, Jan Berger, A. Mark Fendrick, Felicia Forma, Dana Goldman, Anne Peters Harmel, Rebecca Killion, **Darius N. Lakdawalla,** Douglas Owens and Joe Stahl. "Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes." *American Journal of Managed Care*, vol. 19, no. 2, 2013, pp. 93-96.
39. Bognar, Katalin, Kelly Bell, **Darius N. Lakdawalla**, Anshu Shrestha, Julia Snider, N Thomas and Dana Goldman. "Clinical Outcomes Associated with Rates of Sulfonylurea Use among Physicians." *American Journal of Managed Care: Evidence-Based Diabetes*, vol. 19, 2013, pp. SP182-186.
40. Yin, Wesley, John Penrod, Ross Maclean, **Darius N. Lakdawalla** and Tomas Philipson. "Value of Survival Gains in Chronic Myeloid Leukemia." *American Journal of Managed Care*, vol. 18, no. 11 Suppl, 2012, pp. S257-264.
41. Seabury, Seth, Dana Goldman, J. Ross Maclean, John Penrod and **Darius N. Lakdawalla**. "Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown through Traditional Estimates." *Health Affairs*, vol. 31, no. 4, 2012, pp. 691-699.
42. Philipson, Tomas, Michal Eber, **Darius N. Lakdawalla**, Mitra Corral, Rena Conti and Dana Goldman. "An Analysis of Whether Higher Health Care Spending in the United States Versus Europe Is 'Worth It' in the Case of Cancer." *Health Affairs*, vol. 31, no. 4, 2012, pp. 667-675.
43. **Lakdawalla, Darius N.,** John Romley, Yuri Sanchez, J. Ross Maclean, John Penrod and Tomas Philipson. "How Cancer Patients Value Hope and the Implications for Cost-Effectiveness Assessments of High-Cost Cancer Therapies." *Health Affairs*, vol. 31, no. 4, 2012, pp. 676-682.
44. Grabowski, David, **Darius N. Lakdawalla**, Dana Goldman, Michael Eber, Larry Liu, Tamer Abdelgawad, Andreas Kuznik, Michael Chernew and Tomas Philipson. "The Large Social Value Resulting from Use of Statins Warrants Steps to Improve Adherence and Broaden Treatment." *Health Affairs*, vol. 31, no. 10, 2012, pp. 2276-2285.
45. Darkow, Theodore, J. Ross Maclean, Geoffrey Joyce, Dana Goldman and **Darius N. Lakdawalla**. "Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia." *American Journal of Managed Care*, vol. 18, no. 11 Suppl, 2012, pp. S272-278.
46. Michaud, Pierre-Carl, Dana Goldman, **Darius N. Lakdawalla**, Adam Gailey and Yuhui Zheng. "Differences in Health between Americans and Western Europeans: Effects on Longevity and Public Finance." *Social Science and Medicine*, vol. 73, no. 2, 2011, pp. 254-263.
47. Goldman, Dana, **Darius N. Lakdawalla**, Jesse Malkin, John Romley and Tomas Philipson. "The Benefits from Giving Makers of Conventional 'Small Molecule' Drugs Longer Exclusivity over Clinical Trial Data." *Health Affairs*, vol. 30, no. 1, 2011, pp. 84-90.
48. Sun, Eric, Anupam Jena, **Darius N. Lakdawalla**, Carolina Reyes, Tomas Philipson and Dana Goldman. "The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains." *Forum for Health Economics and Policy*, vol. 12, no. 2, 2010, pp. 1-22.
49. Jena, Anupam, Dana Goldman, Amee Kamdar, **Darius N. Lakdawalla** and Yang Lu. "Sexually Transmitted Diseases among Users of Erectile Dysfunction Drugs: Analysis of Claims Data." *Annals of Internal Medicine*, vol. 153, no. 1, 2010, pp. 1-7.
50. Goldman, Dana, Pierre-Carl Michaud, **Darius N. Lakdawalla**, Yuhui Zheng, Adam Gailey and Igor Vaynman. "The Fiscal Consequences of Trends in Population Health." *National Tax Journal*, vol. 63, no. 2, 2010, pp. 307-330.
51. Gailey, Adam, **Darius N. Lakdawalla** and Neeraj Sood. "Patents, Innovation, and the Welfare Effects of Medicare Part D." *Advances in Health Economics and Health Services Research*, vol. 22, 2010, pp. 317-344.
52. Chen, Er, Mark Looman, Marianne Laouri, Meghan Gallagher, Karen Van Nuys, **Darius N. Lakdawalla** and Joan Fortuny. "Burden of Illness of Diabetic Macular Edema: Literature Review." *Current Medical Research and Opinion*, vol. 26, no. 7, 2010, pp. 1587-1597.
53. Stewart, Kate, David Grabowski and **Darius N. Lakdawalla**. "Annual Expenditures for Nursing Home Care: Private and Public Payer Price Growth, 1977 to 2004." *Medical Care*, vol. 47, no. 3, 2009, pp. 295-301.
54. Sood, Neeraj, Han de Vries, Italo Gutierrez, **Darius N. Lakdawalla** and Dana Goldman. "The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries." *Health Affairs,* vol. 28, no. 1, 2009, pp. w125-137.
55. **Lakdawalla, Darius N.,** Dana Goldman, Pierre-Carl Michaud, Neeraj Sood, Robert Lempert, Ze Cong, Han de Vries and Italo Gutierrez. "U.S. Pharmaceutical Policy in a Global Marketplace." *Health Affairs*, vol. 28, no. 1, 2009, pp. w138-150.
56. **Lakdawalla, Darius N.,** Dana Goldman, Pierre-Carl Michaud, Neeraj Sood, Robert Lempert, Ze Cong, Han de Vries and Igor Gutierrez. "U.S. Pharmaceutical Policy in a Global Marketplace." *Health Affairs*, vol. 28, no. 1, 2009, pp. W138-W150.
57. Goldman, Dana, Anupam Jena, **Darius N. Lakdawalla**, Jennifer Malin, Jesse Malkin and Eric Sun. "The Value of Specialty Oncology Drugs." *Health Services Research*, 2010, vol. 45, no. 1, pp. 115-132.
58. Bhattacharya, Jayanta, Kavita Choudhry and **Darius N. Lakdawalla**. "Chronic Disease and Trends in Severe Disability in Working Age Populations." *Medical Care*, vol. 46, no. 1, 2008, pp. 92-100.
59. **Lakdawalla, Darius** and George Zanjani. "Terrorism Insurance Policy and the Public Good." *St. John's Journal of Legal Commentary*, vol. 18, no. 2, 2005, pp. 463-469.
60. **Lakdawalla, Darius N.,** Dana Goldman and Baoping Shang. "The Health and Cost Consequences of Obesity among the Future Elderly." *Health Affairs*, vol. 24 Suppl 2, 2005, pp. W5R30-41.
61. Goldman, Dana, Baoping Shang, Jay Bhattacharya, Alan Garber, Michael Hurd, Geoffrey Joyce, **Darius N. Lakdawalla**, Constantijn Panis and Paul Shekelle. "Consequences of Health Trends and Medical Innovation for the Future Elderly." *Health Affairs*, vol. 24 Suppl 2, 2005, pp. W5R5-17.
62. **Lakdawalla, Darius N.,** Jay Bhattacharya and Dana Goldman. "Are the Young Becoming More Disabled?" *Health Affairs*, vol. 23, no. 1, 2004, pp. 168-176.
63. **Lakdawalla, Darius** and Robert Schoeni. "Is Nursing Home Demand Affected by the Decline in Age Difference between Spouses." *Demographic Research*, vol. 8, no. 10, 2003.
64. **Lakdawalla, Darius N.,** Jay Bhattacharya, Dana Goldman, Michael Hurd, Geoffrey Joyce and Constantijn Panis. "Forecasting the Nursing Home Population." *Medical Care*, vol. 41, no. 1, 2003, pp. 8-20.

#### *Medical Literature*

1. Lin, Eugene, Glenn Chertow, Jay Bhattacharya, and **Darius Lakdawalla**. “Early Delays in Insurance Coverage and Long-Term Use of Home-based Peritoneal Dialysis.” *Medical Care*, 58(7): 632-642, July 2020.
2. Lichtenstein, Gary R., Ahva Shahibi, Seth A. Seabury, **Darius N. Lakdawalla**, Oliver Diaz Espinosa, Sarah Green, Michelle Brauer, Robert N. Baldassano. “Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis.” *Clinical Gastroenterology and Hepatology* 2020; 18(4):889-897.
3. Li, Meng, **Darius N. Lakdawalla**, Dana P. Goldman. “The association between spending and outcomes for cancer patients.” *Journal of Clinical Oncology*, December 5, 2019.
4. Mattke, Soeren, Stefan Schneider, Patrick Orr, **Darius N. Lakdawalla**, and Dana Goldman. “Temporal trends in mortality after transcatheter aortic valve replacement: a systematic review and meta-regression analysis.” *Structural Heart*, November 24, 2019, DOI: 10.1080/24748706.2019.1689321.
5. Lichtenstein, Gary R., Ahva Shahibi, Seth A. Seabury, **Darius N. Lakdawalla**, Oliver Diaz Espinosa, Sarah Green, Michelle Brauer, Robert N. Baldassano. “Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis.” *Clinical Gastroenterology and Hepatology* (2019), DOI: <https://doi.org/10.1016/j.cgh.2019.07.022>.
6. MacEwan, Joanna P., Alison R. Silverstein, Jason Shafrin, **Darius N. Lakdawalla**, Ainslie Hatch, Felicia M. Forma. “Medication Adherence Patterns Among Patients with Multiple Serious Mental and Physical Illnesses.” *Advances in Therapy*, 35(5), May 2018, pp. 671-685.
7. Shrestha, Anshu, Adi Eldar-Lissai, Ningqi Hou, **Darius N. Lakdawalla** and Katharine Batt. "Real-World Resource Use and Costs of Haemophilia a-Related Bleeding." *Haemophilia*, vol. 23, no. 4, 2017, pp. e267-e275.
8. Shafrin, Jason, Suepattra May, Anshu Shrestha, Charles Ruetsch, Nicole Gerlanc, Felicia Forma, Ainslie Hatch, **Darius N. Lakdawalla** and Jean-Pierre Lindenmayer. "Access to Credible Information on Schizophrenia Patients' Medication Adherence by Prescribers Can Change Their Treatment Strategies: Evidence from an Online Survey of Providers." *Patient Preference and Adherence*, vol. 11, 2017, pp. 1071-1081.
9. Jena, Anupam, Jie Zhang and **Darius N. Lakdawalla**. "The Trade-Off between Speed and Safety in Drug Approvals." *JAMA Oncology*, vol. 3, no. 11, 2017, pp. 1465-1466.
10. Snider, Julia, Anupam Jena, Mark Linthicum, Refaat Hegazi, Jamie Partridge, Chris LaVallee, **Darius N. Lakdawalla** and Paul Wischmeyer. "Effect of Hospital Use of Oral Nutritional Supplementation on Length of Stay, Hospital Cost, and 30-Day Readmissions among Medicare Patients with COPD." *Chest*, vol. 147, no. 6, 2015, pp. 1477-1484.
11. **Lakdawalla, Darius N.,** Jacquelyn Chou, Mark Linthicum, Joanna MacEwan, Jei Zhang and Dana Goldman. "Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer." *JAMA Oncology*, vol. 1, no. 2, 2015, pp. 196-202.
12. Snider, Julia, Mark Linthicum, Yanyu Wu, Chris LaVallee, **Darius N. Lakdawalla**, Refaat Hegazi and Laura Matarese. "Economic Burden of Community-Based Disease-Associated Malnutrition in the United States." *Journal of Parenteral and Enteral Nutrition*, vol. 38, no. 2 Suppl, 2014, pp. 77S-85S0.
13. **Lakdawalla, Darius N.,** Maria Mascarenhas, Anupam Jena, Jackie Vanderpuye-Orgle, Chris LaVallee, Mark Linthicum and Julia Snider. "Impact of Oral Nutrition Supplements on Hospital Outcomes in Pediatric Patients." *Journal of Parenteral and Enteral Nutrition*, vol. 38, no. 2 Suppl, 2014, pp. 42S-49S.
14. **Lakdawalla, Darius N.,** Anupam Jena and Jason Doctor. "Careful Use of Science to Advance the Debate on the UK Cancer Drugs Fund." *The Journal of the American Medical Association*, vol. 311, no. 1, 2014, pp. 25-26.
15. Turakhia, Mintu, Matthew Solomon, Mehul Jhaveri, Pamela Davis, Michael Eber, Ryan Conrad, Nicholas Summers and **Darius N. Lakdawalla**. "Burden, Timing, and Relationship of Cardiovascular Hospitalization to Mortality among Medicare Beneficiaries with Newly Diagnosed Atrial Fibrillation." *American Heart Journal*, vol. 166, no. 3, 2013, pp. 573-580.
16. Solomon, Matthew, Sandeep Vijan, Felicia Forma, Ryan Conrad, Nicholas Summers and **Darius N. Lakdawalla**. "The Impact of Insulin Type on Severe Hypoglycaemia Events Requiring Inpatient and Emergency Department Care in Patients with Type 2 Diabetes." *Diabetes Research and Clinical Practice*, vol. 102, no. 3, 2013, pp. 175-182.
17. Seabury, Seth, Amitabh Chandra, **Darius N. Lakdawalla** and Anupam Jena. "Defense Costs of Medical Malpractice Claims." *The New England Journal of Medicine*, vol. 366, no. 14, 2012, pp. 1354-1356.
18. Jena, Anupam, Amitabh Chandra, **Darius N. Lakdawalla** and Seth Seabury. "Outcomes of Medical Malpractice Litigation against Us Physicians." *Archives of Internal Medicine*, vol. 172, no. 11, 2012, pp. 892-894.
19. Jena, Anupam, Seth Seabury, **Darius N. Lakdawalla** and Amitabh Chandra. "Malpractice Risk According to Physician Specialty." *The New England Journal of Medicine*, vol. 365, no. 7, 2011, pp. 629-636.
20. Faulkner, Guy, Paul Grootendorst, Van Nguyen, Tatiana Andreyeva, Kelly Arbour-Nicitopoulos, M. Christopher Auld, Sean Cash, John Cawley, Peter Donnelly, Adam Drewnowski, Laurette Dubé, Roberta Ferrence, Ian Janssen, Jeffrey Lafrance, **Darius N. Lakdawalla**, Rena Mendelsen, Lisa Powell, W. Bruce Traill and Frank Windmeijer. "Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey." *International Journal of Behavioral Nutrition and Physical Activity*, vol. 8, 2011, p. 109.

#### Published conference abstracts

1. Phelps, Charles, and **Darius N. Lakdawalla**, “Evaluation of Medical Technologies with Uncertain Benefits.” *Value in Health* 22: S774, 2019.
2. Lin, Eugene, Glenn Chertow, Jayanta Bhattacharya, and **Darius N. Lakdawalla**. “The impact of short-term gaps in insurance coverage on long-term peritoneal dialysis use: an instrumental variable analysis.” AcademyHealth, 2019 Annual Research Meeting.
3. MacEwan, Joanna P., Lauren Zhao, Katie Everson, Larry Liu, Sun Fang, and **Darius N. Lakdawalla**. “Evolving Clinical Benefits and Social Value of Lipid Lowering Therapies.” *Circulation: Cardiovascular Quality and Outcomes*, 12(Suppl. 1): A146-A146, April 2019.
4. Baumgardner, James, Katie Everson, Michelle Brauer, Jie Zhang, Yanni Hao, Jamae Liu, and **Darius N. Lakdawalla**. “CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments.” *Blood* 132(Suppl. 1): 322, November 21, 2018.
5. Jansen, Jeroen, Devin Incerti, Jason Shafrin, A.M. Frederickson, **Darius N. Lakdawalla**, and Karen Reckamp. “A flexible open-source cost-effectiveness model for metastatic EGFR+ non-small cell lung cancer.” *Value in Health* 21: S42-S43, October 1, 2018.
6. Incerti, Devin, Jason Shafrin, **Darius N. Lakdawalla**, Lauren Zhao, Mark Linthicum, and Jeroen Jansen. “Improvement of an open-source cost-effectiveness model based on public feedback.” *Value in Health* 21: S42, October 1, 2018.
7. Shafrin, Jason, **Darius N. Lakdawalla**, Joanna MacEwan, Alison Silverstein, Adam Hatch and Felicia Forma. "Adherence Patterns among Patients Using Oral Atypical Antipsychotics and Other Medications." *Value in Health*, vol. 20, no. 9, 2017, pp. A403-A403.
8. Mulligan, Karen, Thanh Ton, Lara Yoon, Susan Boklage, Andreas Kuznik, Jesse Sullivan, Mina Kabiri, Mary Panaccio, Keiko Higuchi and **Darius N. Lakdawalla**. "Measuring Indirect Costs (Productivity and Caregiver Burden) in the ACC/AHA Guideline Statin Benefit Groups." *Value in Health*, vol. 20, no. 5, 2017, pp. A269-A269.
9. Sullivan, Jeff, Alison Ward, Beata Korytowsky, Desi Peneva, Jennifer Benner, **Darius N. Lakdawalla**, Bjorn Bolinder, Robert Figlin, and Anupam Jena. "The Social Value of Immunotherapy in Non-Small Cell Lung Cancer." *Value in Health*, vol. 19, no. 3, 2016, pp. A167-A167.
10. **Lakdawalla, Darius N.,** Joanna MacEwan, Adrian Towse, Mikel Berdud, Kimberly Westrich and Robert Dubois. "Estimating the Lifetime Price of Pharmaceuticals: What Are the Long-Term Costs to Society?" *Value in Health*, vol. 19, no. 3, 2016, pp. A273-A273.
11. Shrestha, Anshu, Adi Eldar-Lissai, Yanyu Wu, Katherin Batt, Sangeeta Krishnan and **Darius N. Lakdawalla**. "A New Method for Counting Hemophilia-Related Bleeding Events in Claims Data." *Value in Health*, vol. 18, no. 3, 2015, pp. A2-A2.
12. Snider, Julia, Mark Linthicum, Chris LaVallee and **Darius N. Lakdawalla**. "The Impact of Oral Nutritional Supplementation in Medicare Patients with COPD." *Value in Health*, vol. 17, no. 3, 2014, pp. A179-A180.
13. Seabury, Seth, **Darius N. Lakdawalla**, Deborah Walter, John Hayes, Thomas Gustafson, Anshu Shrestha and Dana Goldman. "Medicaid Formulary Restrictions and Expenditures for Patients with Major Depressive Disorder." *Value in Health*, vol. 17, no. 3, 2014, pp. A222-A222.
14. **Lakdawalla, Darius N.,** Julia Thornton, Daniella Perlroth, Chris LaVallee, Mark Linthicum, Tomas Philipson, Jamie Partridge and Paul Wischmeyer. "Effect of Oral Nutritional Supplements on Hospital Outcomes in Patients Aged 65+ with Congestive Heart Failure." *Value in Health*, vol. 17, no. 7, 2014, p. A503.
15. Stevens, Warren, Laura Henkhaus, Julia Snider and **Darius N. Lakdawalla**. "A Comparison of the Cost-Effectiveness of Low-Cost Unreimbursed Health Technologies and Commonly Reimbursed Drug Therapies." *Value in Health*, vol. 16, no. 3, 2013, pp. A259-A260.
16. Bognar, Katalin, Kelly Bell, **Darius N. Lakdawalla**, Anshu Shrestha, Julia Snider, Nina Thomas and Dana Goldman. "Health Care Costs and Clinical Outcomes Associated with Rates of Sulfonylurea Use by Physicians." *Value in Health*, vol. 16, no. 3, 2013, pp. A173-A174.
17. Pritchard, Daryl, Michael Eber, Marco Huesch, Robert Dubois and **Darius N. Lakdawalla**. "Impact of Comparative Effectiveness Research on Biomedical Innovation and Population Health." *Value in Health*, vol. 16, no. 3, 2013, pp. A266-A266.
18. **Lakdawalla, Darius N.,** Dana Goldman and Tomas Philipson. "Modeling the Health and Medical Care Spending of the Future Elderly: An Update Using the Future Elderly Model." *Value in Health*, vol. 15, no. 4, 2012, pp. A195-A196.
19. Dana Goldman, **Darius N. Lakdawalla** and Tomas Philipson. "Market Exclusivity for Drugs: The Authors Reply." *Health Affairs*, vol. 30, no. 4, 2011.
20. Zheng, Yuhui, Dana Goldman, Pierre-Carl Michaud, **Darius N. Lakdawalla**, Geoffrey Joyce, Igor Vaynman and Adam Gailey. "Projecting the Burden of Alzheimer's Disease and Evaluating the Potential Impacts of Preventing Alzheimer's Disease in the United States." *Value in Health*, vol. 13, no. 3, 2010, pp. A144-A144.
21. Sun, Eric, **Darius N. Lakdawalla**, Carolina Reyes, Dana Goldman, Tomas Philipson and Anupam Jena. "The War on Cancer: An Economic Evaluation of Recent Gains in Cancer Survival." *Value in Health*, vol. 11, no. 3, 2008, pp. A82-A82.

#### Other Publications

1. **Lakdawalla, Darius** and Charles Phelps. “Evaluation of Medical Technologies with Uncertain Benefits.” *American Journal of Managed Care: Clinical Brief*. February 2020.
2. Goldman, Dana and **Darius N. Lakdawalla**. “Health Care’s Killer App: Life Insurance.” *Wall Street Journal* op-ed, March 20, 2019.
3. Mattke, Soren, **Darius N. Lakdawalla**, and Dana Goldman. “The Long Road to Value-Based Payment: The Case of Transcatheter Aortic Valve Replacement.” *Health Affairs Blog,* July 26, 2018.
4. Conti, Rena, and **Darius N. Lakdawalla**. “Putting More into Biopharmaceutical Value Assessments.” *Health Affairs Blog*, January 3, 2018.
5. Chou, Jacquelyn, Glenn Chertow, **Darius N. Lakdawalla**, Alon Yehoshua, and Vasily Belozeroff. “Bundled Payments: Balancing Incentives, Quality, and Affordability.” *Health Affairs Blog*, December 20, 2017.
6. Goldman, Dana and **Darius N. Lakdawalla**. “Take Me Out to the Pill Game.” *Wall Street Journal* op-ed, June 19, 2017.
7. **Lakdawalla, Darius N.,** Anup Malani, and Jay Bhattacharya. “Why America Needs a Do-Over on Medicaid Reform.” *The Conversation*, May 11, 2017.
8. Balch, Alan, and **Darius N. Lakdawalla**. “The Case for Patient-Centered Assessment of Value.” *Health Affairs Blog*, May 8, 2017.
9. Sachs, Rachel, Nicholas Bagley, and **Darius N. Lakdawalla**. “Value-Based Pricing for Pharmaceuticals in the Trump Administration.” *Health Affairs Blog*, April 27, 2017.
10. Jena, Anupam, and **Darius N. Lakdawalla**. “Value Frameworks for Rare Diseases: Should They Be Different?” *Health Affairs Blog*, April 12, 2017.
11. **Lakdawalla, Darius N.,** and Anup Malani. “How Republicans and Democrats Can Both Keep Their Promises on Health Care.” *The Conversation*, March 2, 2017.
12. **Lakdawalla, Darius N.,** and Anup Malani. “Do You Know What the Affordable Care Act Does? Here’s a Primer to Help.” *The Conversation*, February 27, 2017.
13. **Lakdawalla, Darius N.,** Mark Linthicum and Jackie Vanderpuye-Orgle. "Does Patient Cost Sharing for HCV Drugs Make Sense?" *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP188-190.
14. **Lakdawalla, Darius N.,** and Dana Goldman. “Why Academics Consulting with Industry on Health Care May Be an Idea Whose Time Has Come.” *The Conversation*, December 21, 2016.
15. Goldman, Dana, and **Darius N. Lakdawalla**. “Election Verdict: Pharma Needs a New Prescription.” *StatNews*, November 10, 2016.
16. Philipson, Tomas, and **Darius N. Lakdawalla**. “All or Nothing? Rethinking the FDA Approval Framework.” *Forbes*, November 4, 2016.
17. **Lakdawalla, Darius N.,** and Peter Neumann. “Budget Criteria and Value Assessments: A Case of Apples and Oranges?” *Health Affairs Blog*, September 22, 2016.
18. **Lakdawalla, Darius N.,** and Julian Reif. “Health, body weight, and obesity.” *The Oxford Handbook of Economics and Human Biology*, 2016.
19. Goldman, Dana P., **Darius N. Lakdawalla**, James R. Baumgardner, and Mark T. Linthicum. “Are Biopharmaceutical Budget Caps Good Public Policy?” *The Economists’ Voice* 13(1):27-42, 2016.
20. **Lakdawalla, Darius N.,** Anup Malani, and Julian Reif. “The Complex Relationship Between Healthcare Reform and Innovation.” *The Future of Healthcare Reform in the United States,* Anup Malani and Michael H. Schill, eds., University of Chicago Press, 2015.
21. **Lakdawalla, Darius**. (2015, September 23). “Drug Price Controls End Up Costing Patients Their Health.” *New York Times*, Retrieved from <http://www.nytimes.com/roomfordebate/2015/09/23/should-the-government-impose-drug-price-controls/drug-price-controls-end-up-costing-patients-their-health>
22. Goldman, Dana, and **Darius N. Lakdawalla**. “Moving Beyond Price-Per-Dose in the Pharmaceutical Industry.” Web blog post. *Health Affairs Blog*. Health Affairs, 30 September 2015. Web.
23. Goldman, Dana, **Darius N. Lakdawalla**, and Lee Newcomer. “It’s Time for Value-Based Payment in Oncology.” Web blog post. *Health Affairs Blog*. Health Affairs, 28 April 2015. Web.
24. Goldman, Dana, **Darius N. Lakdawalla**, and Tomas Philipson. “Morality versus Survival in International Comparisons of Cancer Care.” Web blog post. *Health Affairs Blog*. Health Affairs, 20 March 2015. Web.
25. Dayoub, Elias, Anupam Jena, and **Darius N. Lakdawalla**. “The End of the Blockbuster? Implications for Pricing of New Drugs.” Web blog post. *Health Affairs Blog*. Health Affairs, 16 June 2014. Web.
26. Goldman, Dana, Adam Leive and **Darius N. Lakdawalla**. "Want More Value from Prescription Drugs? We Need to Let Prices Rise and Fall?" *The Economists' Voice*, vol. 10, no. 1, 2013, pp. 39-43.
27. **Lakdawalla, Darius N.,** Jay Bhattacharya, Amitabh Chandra, Michael Chernew, Dana Goldman, Anupam Jena, Anup Malani, and Tomas Philipson. “Best of Both Worlds: Uniting Universal Coverage and Personal Choice in Health Care.” *American Enterprise Institute*, August 2013.
28. Seabury, Seth, Darius N. Lakdawalla and Dana Goldman. "Patients' Willingness to Pay: The Authors Reply." *Health Affairs*, vol. 31, no. 8, 2012, doi:10.1377/hlthaff.2012.0713.
29. Marco Huesch and Darius N. Lakdawalla. "Freedom to Innovate: The Perils of Centralized Medical Research." *Archives of Internal Medicine*, vol. 172, no. 21, 2012, pp. 1692-1693; author reply 1693.
30. Goldman, Dana, Steven Schwartz, **Darius N. Lakdawalla**, Tomas Philipson, and Anupam Jena. “Harnessing the Promise of Comparative Effectiveness Research.” Web blog post. *Health Affairs Blog*. Health Affairs, 12 September 2012. Web.
31. Eber, Michael, Dana Goldman, **Darius N. Lakdawalla**, and Tomas Philipson. “When Epidemiology Goes Astray: Valuing Cancer Care in the Unites States and Europe.” Web blog post. *Health Affairs Blog*. Health Affairs, 14 May 2012. Web.
32. Chernew, Michael, **Darius N. Lakdawalla**, and Dana Goldman. “Saving Medicare Dollars: Moving from the SGR to Bundled Payments.” Web blog post. *Health Affairs Blog*. Health Affairs, 24 February 2012. Web.
33. Goldman, Dana, and **Darius N. Lakdawalla.**  “Intellectual Property.” *Handbook of Health Economics*, Chapter 13, New York: Elsevier Science, 2012.
34. **Lakdawalla, Darius N.,** and Neeraj Sood. “Incentives to Innovate.” *Oxford Handbook of the Economics of the BioPharmaceutical Industry*. New York: Oxford, 2012.
35. Seabury, Seth, Amitabh Chandra, **Darius N. Lakdawalla** and Anupam Jena. “Defense Costs of Medical Malpractice Claims.” *The New England Journal of Medicine*. 2012.
36. Huckfeldt, Peter, **Darius N. Lakdawalla,** and Tomas J. Philipson. “Economics of Obesity.” *Elgar Companion to Health Economics, 2nd Edition*, Chapter 7 (2), 2012.
37. Goldman, Dana, **Darius N. Lakdawalla,** and Yuhui Zheng. “Food Prices and the Dynamics of Body Weight.” *Economic Aspects of Obesity*. Chicago: University of Chicago Press, 2011.
38. Goldman, Dana, Darius N. Lakdawalla, Tomas Philipson and Wesley Yin. "Valuing Health Technologies at NiICE: Recommendations for Improved Incorporation of Treatment Value in HTA." *Health Econ*, vol. 19, no. 10, 2010, pp. 1109-1116.
39. Gailey, Adam, **Darius N. Lakdawalla,** and Neeraj Sood. “Patents, Innovation, and the Welfare Effects of Medicare Part D.” *Advances in Health Economics and Health Services Research*. New York: Elsevier, 2010.
40. Goldman, Dana and **Darius N. Lakdawalla.** “Can the ACA Improve Population Health?” *The Economists’ Voice* 7 (5): Article 4. December 2010.
41. Goldman, Dana, **Darius N. Lakdawalla,** Tomas Philipson, and Wesley Yin. “Valuing Health Technologies at Nice: Recommendations for Improved Incorporation of Treatment Value in HTA.” *Health Economics* 19 (10): 1109-1116. October 2010.
42. **Lakdawalla, Darius** and Tomas Philipson. “Economics of Obesity.” *Elgar Companion to Health Economics*. Cambridge: Edward Elgar, 2006.
43. **Lakdawalla, Darius N.,** Tomas Philipson and Jay Bhattacharya. "Welfare-Enhancing Technological Change and the Growth of Obesity." *American Economic Review: AEA Papers and Proceedings*, vol. 95, no. 2, 2005, pp. 253-257.
44. Bhattacharya, Jay, David Cutler, Dana Goldman, Michael Hurd, Geoffrey Joyce, **Darius N. Lakdawalla,** Constantijn Panis and Baoping Shang. "Disability Forecasts and Future Medicare Costs." *Frontiers in Health Policy Research*, edited by David Cutler and Alan M. Garber, vol. 7, MIT Press, 2004.
45. **Lakdawalla, Darius N.,** and George Zanjani. “Terrorism Insurance Policy and the Public Good.” *St. John’s Journal of Legal Commentary* 18(2): 463-469, Spring 2004.
46. Bhattacharya, Jay, David Cutler, Dana Goldman, Michael Hurd, Geoffrey Joyce, **Darius N. Lakdawalla,** Constantijn Panis, and Baoping Shang. “Disability Forecasts and Future Medicare Costs.” *Forum for Health Economics and Policy,* 7(1), Jan 2004.
47. **Lakdawalla, Darius N.,** Jay Bhattacharya and Dana Goldman. "A Response to the Points by Manton and Williamson." *Medical Care*, vol. 41, no. 1, 2003, pp. 28-31.
48. **Lakdawalla, Darius**. "Quantity over Quality." *Education Next*, 2002, pp. 66-72.
49. Goldman, Dana and Darius N. Lakdawalla. "A New Method for Determining Patient Payments for Outpatient Drugs." *American Journal of Managed Care*, vol. 8, no. 2, 2002, pp. 125, 128, 130.
50. Goldman, Dana, and **Darius N. Lakdawalla.**  “Comment on ‘A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost.’” *American Journal of Managed Care* 8(2): 125-8, February 2002.
51. **Lakdawalla, Darius N.,** and Tomas Philipson. “Public Financing and the Market for Long-Term Care.” *Frontiers in Health Policy Research 4*, edited by Alan Garber, NBER. Chicago: University of Chicago Press, 2001.
52. Philipson, Tomas, and **Darius N. Lakdawalla**. “Medical Care Output and Productivity in the Nonprofit Sector.” In *Medical Care Output and Productivity*, edited by David Cutler and Ernst Berndt. NBER Studies in Income and Wealth, Volume 62. Chicago: University of Chicago Press, 2001.

#### Current Working Papers

1. **Lakdawalla, Darius N.**, Neeraj Sood and Abby Alpert. “Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D.” National Bureau of Economic Research Working Paper 21714.
2. Bauer, Daniel, **Darius N. Lakdawalla,** and Julian Reif. “Risk, Uncertainty, and the Value of Life.” National Bureau of Economic Research Working Paper 25055.
3. **Lakdawalla, Darius N.**, Amanda Starc, and Wesley Yin. “Economic incentives and outcomes in the market for oncology treatment.” Working Paper.
4. Chen, Alice, Partha Deb, and **Darius N. Lakdawalla**. “Can higher profitability raise pharmaceutical R&D costs? Evidence from Medicare Part D.” Working Paper.

#### Grants

1. *Co-Principal Investigator, National Institute on Aging, R01 Grant Award*. “Ensuring Access to Novel Alzheimer’s and Dementia Treatments: Evaluating Innovative Payment Approaches.” (Co-Principal Investigator: Dana Goldman)
2. *Co-Project Leader, Covered CA, Grant Submission.* “Evaluating Performance in the California Healthcare Exchanges.” $75,000 total. (Co-Project Lead: Wesley Yin)
3. *Co-Principal Investigator, National Institute of Aging, R01 Grant Submission*. “Physician Perceptions of Medical Malpractice.” (Co-Principal Investigator: Seth Seabury)
4. *Project Lead, National Institute of Health, P01 Grant Award.* March 2012-February 2016. “The Behavioral Effects of Prescription Drug Use.” 4 years, $1,888,468 total. (Co-Project Lead: Robert Kaestner)
5. *Principal Investigator, National Institute on Aging, R01 Grant Award.* May 2009-May 2013. “Medical Malpractice, Health Care Costs, and Technology Adoption.” 4 years, $1,300,000 total. (Co-Principal Investigator: Seth Seabury.)
6. *Co-Project Leader, National Institute on Aging, P01 Grant Award*. July 2005-June 2010. “Causes and Consequences of Obesity Among Older Americans.” (Principal Investigator: Michael Hurd. Project Leader: Dana Goldman)
7. *Co-Principal Investigator, National Institute on Aging, R01 Grant Award.* July 2006-June 2010. “Obesity Among Older Americans.” (Principal Investigator: Dana Goldman)
8. *Principal Investigator, National Institute on Aging, R01 Grant Award.* August 2004-August 2007. “Whom Does Medicare Benefit?” 3 years, $696,000 total. (Co-Principal Investigators: Jay Bhattacharya and Michael Schoenbaum)
9. *Principal Investigator, National Institute on Aging, R03 Grant Award.* June 2005-May 2007. “Medical Malpractice: Implications for Cost and Technology.” 2 years, $174,000 total. (Co-Principal Investigator: Seth Seabury.)
10. *Co-Principal Investigator, National Institute of Child Health and Human Development, R03 Grant Award*. September 2004-August 2006. “Childlessness: Choice or Chance?” 2 years, $174,000 total. (Principal Investigator: David Loughran. Co-Principal Investigator: Julie Zissimopoulos.)
11. *Principal Investigator, National Institute of Occupational Safety and Health, R03 Grant Award*. August 2002-August 2004. “Unclaimed Injuries and Workers’ Compensation Adequacy.” 2-year, $172,000 total. (Co-Principal Investigator: Robert Reville.)
12. *Principal Investigator, National Institute on Aging, R03 Grant Award*. September 2001-September 2002. “The Redistributive Effects of Medicare.” 1 year, $86,000 total. (Co-Principal Investigators: Jay Bhattacharya and Michael Schoenbaum)
13. *Principal Investigator, National Institute on Aging, R03 Grant Award*. May 2001-May 2002. “Age Difference of Spouses and Long-Term Care.” 1 year, $86,000 total. (Co-Principal Investigator: Robert Schoeni)

#### Awards

* *2019 PhRMA Foundation Value Assessment Challenge Award,* Third Place – awards designed to encourage innovative approaches to defining and measuring value in health care.
* *2016 JMCP Award for Excellence­* – awarded annually to recognize an article that represents the best scholarly work in managed care pharmacy, for “Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.”
* *2009 Eugene Garfield Economic Impact of Medical and Health Research Award* – awarded annually to an outstanding paper demonstrating how medical and health research impacts the economy, for “US Pharmaceutical Policy in a Global Marketplace.”
* *2007 Edwin E. and Mary T. Huddleson Award for Outstanding Teaching*, Pardee RAND Graduate School of Public Policy.
* 2003 Milken Institute Award for Distinguished Economic Research — awarded for “Technological Change and the Growth of Obesity.”
* *T.W. Schultz Dissertation Fellowship*, University of Chicago, September 1999-June 2000.
* *Nonprofits Fellowship*, National Bureau of Economic Research, September 1998-1999.
* *Century Scholarship*, University of Chicago, September 1995-June 1999.

#### Teaching Experience

* *Risk Analysis*, University of Southern California School of Policy, Planning and Development and Viterbi School of Engineering. Graduate-level course in the Master’s in Public Policy and Public Policy Doctoral sequences.
* *Introduction to/Fundamentals of Health Policy and Management (PPD325),* University of Southern California School of Policy, Planning and Development. Graduate-level course in the Master’s in Public Policy and Public Policy Doctoral sequences.
* *Health Economics II (PMEP 544)*, University of Southern California School of Policy, Planning, and Development. Graduate-level course in the Public Policy Doctoral sequences.
* *Health Policy (PPD415)*, University of Southern California School of Policy, Planning, and Development. Undergraduate elective in the health policy sequence.
* *Advanced Microeconomics*, Pardee RAND Graduate School of Public Policy, 2003-2009. Co-taught one quarter in Ph.D. microeconomics sequence.
* *Microeconomics Curriculum*, Pardee RAND Graduate School of Public Policy, Fall 2002. Served on 4-person committee that guided the redesign and implementation of a new microeconomics curriculum for the Ph.D. program in Public Policy.

#### Selected Refereeing Activity

* *American Economic Journals*
* *American Economic Review*
* *American Journal of Health Economics*
* *B.E. Journals of Economic Analysis and Policy*
* *Blood Journal*
* *Demography*
* *Econometrica*
* *Economic Inquiry*
* *Economic Journal*
* *Economics and Human Biology*
* *Education Finance and Policy*
* *European Economic Review*
* *Education Next*
* *Forum for Health Economics and Policy*
* *Geneva Papers on Risk and Insurance*
* *Health Affairs*
* *Health Economics*
* *Health Services Research*
* *International Economic Review*
* *International Journal of Health Care Finance and Economics*
* *JAMA Oncology*
* *Journal of the American Medical Association*
* *Journal of Applied Econometrics*
* *Journal of Development Economics*
* *Journal of Economic Literature*
* *Journal of Empirical Legal Studies*
* *Journal of the European Economic Association*
* *Journal of Gerontology: Social Sciences*
* *Journal of Health Economics*
* *Journal of Human Capital*
* *Journal of Human Resources*
* *Journal of Labor Economics*
* *Journal of Policy Analysis and Management*
* *Journal of Political Economy*
* *Journal of Public Economics*
* *Journal of Regional Science*
* *Journal of Risk and Insurance*
* *The Milbank Quarterly*
* *National Tax Journal*
* *New England Journal of Medicine*
* *PharmacoEconomics*
* *Quarterly Journal of Economics*
* *Review of Economic Studies*
* *Review of Economics of the Household*
* *Review of Economics and Statistics*
* *Social Science and Medicine*
* *Social Science Research*
* *Cambridge University Press*
* National Institutes of Health
* National Science Foundation
* US Department of Agriculture Economic Research Service

#### Professional Affiliations

* American Economic Association

#### Selected Popular Press Mentions

* Wapner, Jessica, “Medication keeps getting more expensive – and big pharma won’t explain why.” *Newsweek* (online), April 24, 2018.
* Callery, Taylor, “How to reboot the FDA.” *Politico* (online), December 13, 2017.
* Mason, Melanie, “What would California’s proposed single-payer healthcare system mean for me?” *Los Angeles Times* (online), June 1, 2017.
* Finkl, Ed. “A prescription to help cure high drug costs?” *Medical Economics* (online), May 25, 2017.
* Gregory, Sean and Alexandra Sifferlin, “President Trump Vow to Solve the Opioid Crisis. He Needs to Fix this Problem First.” *Time* (online), February 24, 2017.
* Sharon, Jason and Mark Linthicum, “Advancing Value in Healthcare.” *Genetic Engineering & Biotechnology News* (online), December 12, 2016.
* Hiltzik, Michael, “Will the Trump presidency mean the end of FDA drug regulation?” *Los Angeles Times* (online), November 16, 2016.
* Chang, Alicia, “Prop 61: Big Pharma scores expensive win on California ballot measure.” *The Mercury News* (online), November 10, 2016.
* Associated Press, “Prop 61: Big Pharma scores over drug prices.” *KSBW* (online), November 9, 2016.
* Swaminathan, Nikhil, “Precision medicine may be health care’s next big thing, but we don’t yet know how to evaluate precision drugs.” *Quartz Media* (online), November 1, 2016.
* Pearson, Steven, “Value: Can we afford to think long-term while ignoring budget impact?” *Health Affairs* Blog (online), September 22, 2016.
* Stanton, Dan et al. “Quality for burgeoning US biosimilars market, says BIO panel.” www.biopharma-reporter.com, June 17, 2016.
* Perrone, Matthew, “Apps help people find best drug prices.” *The Columbian* (online). June 6, 2016.
* Perrone, Matthew, “Why not shop for lower prescription drugs prices?” *The Salt Lake Tribune* (online), June 2, 2016.
* Perrone, Matthew, “Why aren’t you shopping for lower prescription drug prices?” www.medicalexpress.com, June 1, 2016.
* Joszt, Laura, “Briefing shed light on the challenges and opportunities of HCV treatment.” *American Journal of Managed Care* (online newsletter), May 27, 2016.
* Plevin, Rebecca, “A financial cast for expanding access to costly hepatitis C drugs,” Southern Caifornia Public Radio (online blog), May 18, 2016.
* Feller, Stephen, “Study: Cheaper to cure hepatitis C sooner than later.” *United Press International* (online), May 9, 2016.
* Perrone, Matthew, “Breakthrough cholesterol drugs fizzle amid price pushback,” *Houston Chronicle* (online), April 22, 2016.
* Perrone, Matthew, “Why so few patients get the new cholesterol busters,” www.cbsnews.com, April 20, 2016.
* *The Economist*, July 30, 2009. “Economics Focus: Waist Banned.” Discussion of Goldman, Dana, Darius N. Lakdawalla, and Yuhui Zheng, “Food Prices and the Dynamics of Body Weight.”
* Steenhuysen, Julie. “Drug Price Controls May Shorten Lives: Report.” *Reuters*, December 16, 2008. Discussion of Lakdawalla, Darius N., et al, “US Pharmaceutical Policy in a Global Marketplace.”
* *The Wall Street Journal*, August 25, 2006. “Econoblog: Cheap Food, Societal Norms and the Economics of Obesity.”
* Morin, Richard. “Breakthrough Breakdown.” *Washington Post*, July 11, 2004, page B5. Review of Goldman, Dana, Darius N. Lakdawalla, and Neeraj Sood, “HIV Breakthroughs and Risky Sexual Behavior.”
* Winslow, Ron. “Obesity Is Linked to Rising Disability in Younger Adults.” *Wall Street Journal*, January 9, 2004, page C1. Review of Lakdawalla, Darius N., Jay Bhattacharya, and Dana Goldman, “Are the Young Becoming More Disabled?”
* Akst, Daniel, *New York Times*, March 2, 2003. “Belt-Loosening in the Work Force.” Mention of Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
* Morin, Richard. “Age-Old Question.” *Washington Post*, January 31, 2003, page B5. Review of: Lakdawalla, Darius N., and Robert Schoeni, “The Decline in the Spousal Age Gap and the Demand for Long-Term Care.”
* Varian, Hal. “Economic Scene: Employment and Prosperity Affect Body Inflation.” *New York Times*, September 26, 2002, page C2. Review of Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
* Sydell, Laura. Radio Interview and Commentary. *Marketplace Morning Report*, National Public Radio. May 30, 2002. Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
* Edmonds, Sarah. Reuters News Service, May 29, 2002. “Innovation Behind Fatter Americans, Study Says.” Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
* Gongloff, Mark. CNN/Money Online, May 21, 2002. “Technology Makes You Fat.” Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
* Critser, Gregory, *Los Angeles Times*, April 28, 2002. “The Price of Pudge.” Mention of Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
* Koretz, Gene. “The Young and the Disabled.” *BusinessWeek*, June 4, 2001, page 30. Review of: Lakdawalla, Darius N., Jay Bhattacharya, and Dana Goldman, “Are the Young Becoming More Disabled?”
* Morin, Richard. “Unhealthy Paradox.” *Washington Post*, May 20, 2001, page B5. Review of: Lakdawalla, Darius N., Jay Bhattacharya, and Dana Goldman, “Are the Young Becoming More Disabled?”
* Postrel, Virginia. “American Waistlines Have Become the Victims of Economic Progress.” *The New York Times*, March 22, 2001, page C2. Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
* *Investor’s Business Daily*, November 30, 1999. “Are Teachers Underpaid?” Review of: Lakdawalla, Darius N., “The Declining Relative Quality of Teachers.”
* Koretz, Gene. “The Coming Boom in Long-Term Care?” *BusinessWeek*, June 28, 1999, page 26. Review of: Lakdawalla, Darius N., and Tomas Philipson, “The Rise in Old-Age Longevity and the Market for Long-Term Care.”

#### SELECTED PRESENTATIONS/ SPEAKING ENGAGEMENTS

* Lakdawalla, Darius. “Economics of the Pharmaceutical Industry.” National Institutes of Health, Special Interest Group, March 5, 2020.
* Lakdawalla, Darius. “Frontiers of Value Assessment in Healthcare.” Allergan, Executive Seminar, December 11, 2019.
* Lakdawalla, Darius. “Mortality Risk, Insurance, and the Value of Life.” Wharton School of Business, November 1, 2019.
* Lakdawalla, Darius. “Mortality Risk, Insurance, and the Value of Life.” Questrom School of Business, Boston University, October 31, 2019.
* Lakdawalla, Darius. “Economics of the Pharmaceutical Industry.” Congressional Budget Office Panel of Health Advisors. September 20, 2019.
* Lakdawalla, Darius. “Novel elements of value in healthcare.” International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, Issue Panel, May 20, 2019.
* Lakdawalla, Darius. “Value-based decision making in Healthcare.” UT-Southwestern Medical School, Guest Lecture to Faculty, February 7, 2019.
* Lakdawalla, Darius. “Food Purchasing Behaviors of New SNAP Recipients.” *Human Capital Economic Opportunity Working Group: Measuring and Improving Health Equity*, Los Angeles, CA, December 7, 2018.
* Lakdawalla, Darius. “The New Economics of Value in Healthcare.” Executive Seminar, Otsuka, Princeton, NJ, November 15, 2018.
* Lakdawalla, Darius. “On Drugs.” Toulouse School of Economics Guest Lecture, Toulouse, France, October 24, 2018
* Lakdawalla, Darius. “Patient Socioeconomic Status and Physician Supply Responses.” *Toulouse School of Economics Industrial/Organizational Seminar*, Toulouse, France, October 15, 2018
* Lakdawalla, Darius. “On Drugs.” *Canadian Health Economist Study Group*, McGill University, Montreal, Canada, May 31, 2018.
* Lakdawalla, Darius. “Should We Move Beyond Conventional Cost-Effectiveness Analysis.” *ISPOR* *Annual Meeting*, Baltimore, MD, May 21, 2018
* Lakdawalla, Darius. “ISPOR’s Special Task Force Report on US Value Assessment Frameworks: A Deeper Dive into Its Health Economic Underpinning.” *ISPOR Annual Meeting*, Boston, MA, May 22, 2017.
* Lakdawalla, Darius. “Actuarial and Health Economic Approaches to Assess Value: Speaking the Same Language or Need for Translation.” *ISPOR Annual Meeting*, Boston, MA, May 22, 2017.
* Lakdawalla, Darius. “A Roadmap to Consumer Clarity in Healthcare Decision Making.” *NPAF’s Spring Policy Consortium*, Washington, DC, May 17, 2017.
* Lakdawalla, Darius. “An Economic Perspective on Value Frameworks.” *AJMC’s ACO and Emerging Healthcare Delivery Coalition*, Scottsdale, AZ, May 5, 2017.
* Lakdawalla, Darius. “Risk Annuitization and the Value of Life.” *HEC Montreal Seminar Series*, Montreal, Quebec, Canada, October 4, 2016.
* Lakdawalla, Darius. “Saving Lives or Saving Money? Understanding the Dual Nature of Physician Preferences.” *Johns Hopkins University Seminar Series*, Baltimore, MD, September 21, 2016.
* Lakdawalla, Darius. Health Economic Perspectives on Value Frameworks: “Measuring Value in Innovative Medicines.” *ASHEcon*, Philadelphia, PA, June 14, 2016.
* Lakdawalla, Darius. The Economics of Reimbursing New Medical Innovation: “An Economic Model of Surrogate Endpoints.” *ASHEcon*, Philadelphia, PA, June 13, 2016.
* Arnsten, Kathleen, Geoffrey Eich, Darius N. Lakdawalla, and Tomas Philipson. “The Future of Biosimilars: How Will Policy and Market Dynamics Impact Patient Value and Access in the U.S.?” *BIO International*, San Francisco, CA, June 8, 2016.
* Lakdawalla, Darius. “Budget Impact Analysis: An Acceptable Part of Value Assessments or a Discordant Concept?” *ISPOR Symposium*, Boston, MA, May 22, 2016.
* Lakdawalla, Darius. “The value of specialty drugs: Can we develop novel access policies for novel medicines?” ISPOR Annual Meeting, Boston, MA, May, 2016.
* Lakdawalla, Darius N., Anupam Jena, and Ryan Cleary. “Ending Hepatitis C: The Value of Curing the Nation’s Deadliest Blood-Borne Disease.” *US Congressional Hearing*, Washington, DC, May 2016.
* Goldman, Dana, Darius N. Lakdawalla, and Sam Nussbaum. “Research and Its Practical Application.” *Academy of Managed Care Pharmacy*, Panel R5, Impact of Value – Designing Innovative Models on Drug Costs, San Francisco, CA, April 2016.
* Lakdawalla. “The Cost and Value of Biomedical Innovation: Implications for Health Policy.” Presentation Title: “What Can We Learn from Recent Hepatitis C Treatments? Understanding the Pricing Process and Spending Consequences for Breakthrough Therapies.” Speaker, *Brookings Institute*, Washington, D.C., October, 2014.
* Lakdawalla. “Forecasting Population Health in Asia.” Keynote Speaker, *Japanese Health Economics Association*, Tokyo, Japan, September 2014.
* Lakdawalla. “Balancing the Value and Cost of Cancer Therapies.” Speaker, *BIO – 2014 International Convention*, San Diego, CA, June 2014.
* Lakdawalla. *ASHEcon – 5th Biennial Meeting*, June 2014.
* Lakdawalla. “Implications of the Affordable Care Act for Diabetes.” Presenter, *74th Scientific Sessions – ADA*, San Francisco, CA, June 2014.
* Lakdawalla. “The Affordable Care Act: Will It Help or Harm the Landscape for Biomedical Innovation and Technology?” Panelist, *ISPOR – 19th Annual International Meeting, Issue Panels – Session IV – Panel#2449*, Montreal, QC, Canada, June 2014.
* Lakdawalla. “The Insurance Value of Medical Innovation.” *National Bureau of Economic Research*- *Annual Conference-Health Economics Program Meeting*, Boston, MA, April 2014.
* Lakdawalla, “The Insurance Value of Medical Innovation.” Guest Lecturer, *School of Public Health, UCSB*, Santa Barbara, CA, March 2014 (Ted Frech)
* Lakdawalla. “The Insurance Value of Medical Innovation.” *National Bureau of Economic Research*- *Annual Conference-Healthcare Program Meeting*, Boston, MA, February 2014.
* Lakdawalla. “Research & Development, Manufacturing, and the Marketplace in California.” *California State Assembly Select Committee on Biotechnology - Information Hearing,* Sacramento, CA, February 2014.
* Lakdawalla, “The Effect of Medicare Part D on bargaining between Drug Companies and Insurance Companies.” Guest Lecturer, *School of Public Health, UCLA*, Los Angeles, CA, January 2014 (Bill Comanor)
* Lakdawalla. “Making the Case for Efforts in Personalized and Precision Health.” *World Economic Forum Annual Summit* *on the Global Agenda*, Abu Dhabi, UAE, November 2013.
* Lakdawalla. “Mental Health and Medicaid Policy.” *Women in Government Annual Healthcare Summit*, Washington, D.C., November 2013.
* Lakdawalla. “The Insurance value of Medical Technology.” *University of Illinois at Urbana-Champaign*, Champaign, IL, October 2013.
* Lakdawalla. *Council for Advancing Diabetes Care*, Santa Monica, CA, October 2013.
* Lakdawalla. “Innovation and Insurance.” *University of Chicago Applications Workshop,* Chicago, IL, September 2013.
* Lakdawalla. “Healthcare/Microeconomics Workshop.” *Indiana University*, Bloomington, IN, September 2013.
* Lakdawalla. “Best of Both Worlds: Uniting Universal Coverage and Personal Choice in Health Care.” *American Enterprise Institute Launch Event*, Washington, D.C., August 2013.
* Lakdawalla. “Promoting Clinical Trials for Cancer.” *PACE Initiative Workshop*, Los Angeles, CA, July 2013.
* Lakdawalla. “Value of Adherence.”/ Session 3: How do we unlock the value of better patient adherence? *AJMC Patient-Centered Diabetes Care Symposium*, Chicago, IL, June 2013.
* Lakdawalla. Panel Discussion of “How Do We Balance Patient Value & Payer Cost in Oncology?” *International Society for Pharmacoeconomics and Outcomes Research* *18th* *Annual International Meeting*, New Orleans, LA, May 2013.
* Lakdawalla. *Council for Advancing Diabetes Care*, Arlington, VA, May 2013.
* Lakdawalla. Discussion of “Hospital Market Structure, Pricing and Quality of Care.” *Allied Social Sciences Association Annual Meeting,* San Diego, CA, January 2013.
* Lakdawalla. “Does Statin Use Adversely Affect Health Behaviors?” *Allied Social Sciences Association Annual Meeting,* San Diego, CA, January 2013.
* Lakdawalla. “Medicare Part D and Negotiating Leverage in the Pharmaceutical Industry.” *University of Chicago Applications of Economics Workshop*, Chicago, IL, May 2010.
* Lakdawalla. Discussion of “The Rise of Paragraph IV Challenges on Startup Alliance Formation in the Pharmaceutical Industry.” *Southern California Applied Microeconomics Conference,* Claremont, CA, April 2010.
* Lakdawalla. “Medicare Part D and Pharmaceutical Advertising.” *Robert Wood Johnson Fellowship External Speaker Series*, Berkeley, CA, March 2010.
* Lakdawalla. “Tort Liability for Prescription Drugs.” *National Bureau of Economic Research Health Care Program Meeting*, Cambridge, MA, March 2010.
* Lakdawalla. “Medicare Part D and Pharmaceutical Advertising.” *American Economic Association Annual Meetings*, Atlanta, GA, January 2010.
* Lakdawalla, “Health Insurance as a Two-Part Pricing Contract.” *Toulouse School of Economics Health Economics Conference*, Toulouse, France, October 2009.
* Lakdawalla, “US Pharmaceutical Policy in a Global Context.” *Eugene Garfield Award Presentation Lunch*, Washington, D.C., October 2009.
* Lakdawalla. “Health Insurance as a Two-Part Pricing Contract.” *Brown University Department of Economics Seminar Series*, Providence, RI, September 2009.